相关实验视频

Updated: Jun 27, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

晚期宫神经内分泌癌中的HER2突变:对特拉斯图祖马布德鲁克斯泰康治疗的影响

Wan-Ru Chao^1,2, Ming-Yung Lee³, Gwo-Tarng Sheu⁴

¹Department of Pathology, Chung-Shan Medical University, Taichung, Taiwan, Republic of China.

Naunyn-Schmiedeberg's archives of pharmacology

|April 30, 2024

概括

在台湾的宫神经内分泌癌 (NEC) 中,HER2突变很常见,这表明trastuzumab deruxtecan (T-DXd) 可能是这种癌症的潜在向治疗方法.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

特拉斯图祖马布德鲁克斯泰坎 (T-DXd) 是一种抗体药物联合物,在晚期的HER2突变非小细胞肺癌 (NSCLC) 中显示出有效性.
宫神经内分泌癌 (NEC) 是一种罕见且具有攻击性的恶性瘤.
探索宫NEC中的HER2突变可能会揭示新的治疗点.

研究的目的:

描述台湾女性患有宫NEC的HER2突变的发病率和类型.
为研究T-DXd作为宫NEC的瘤不可知疗法提供分子理由.

主要方法:

来自台湾患者的12个归档的初级宫NEC样本的分析.
使用Illumina MiSeq.提取DNA并对HER2热点进行向测序.
识别和表征HER2突变,包括位置 (TKD与非TKD).

主要成果:

在12例病例中有5例 (41.7%) 检测到HER2误解突变.
突变主要在氨酸激酶域 (非TKD) 外,包括一种新的T328K变异.
在氨酸激酶域 (TKD) 内没有发现突变.

结论:

在宫NEC中HER2突变的显著率支持进一步的研究.
对于HER2突变的宫NEC患者来说,T-DXd可能是一个有前途的向治疗选择.
这项研究增强了对宫NEC的分子理解,并为未来的治疗策略提供了信息.

关键词:

无神论疗法是一种无神论疗法.抗体与药物的结合物.宫神经内分泌癌的癌症.德鲁克斯可以负载.黄平沈和平汉在这项研究中均为同等贡献.误解突变是一种错误的突变.

更多相关视频

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...